drugset / Trial / NCT00835406

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

NCT00835406

Phase 1 Completed 140 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

The objective of this study is to compare the rate and extent of absorption of alendronate sodium 70 mg tablets (test) versus Fosamax® 70 mg tablets (reference) administered as a single dose of 70 mg under fasting conditions. A review of pharmacokinetic data demonstrates Alendronate Sodium Tablets, 70 mg, manufactured and distributed by TEVA Pharmaceuticals USA are bioequivalent to Fosamax® Tablets, 70 mg, manufactured by Merck Sharp \& Dohme, USA.

Timeline

Start
2000-06
Primary completion
2000-07
Completion
2000-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg

Indications

No indication recorded.